



## 2009 Influenza A (H1N1) Flu Vaccine Information

**OHANA HEALTH PLAN**  
A PLAN OFFERED BY  
WELL-CARE HEALTH INSURANCE OF  
ARIZONA, INC.

December 29, 2009

Dear Clinician:

Due to the recent increased availability of H1N1 vaccine formulations, as well as the increasingly complicated age restrictions for each specific brand and presentation of H1N1 vaccine, we are alerting you of these changes and providing you with a tool to avoid incorrectly administering the vaccine.

Please post the following important document, **2009 Influenza A (H1N1) Flu Vaccine Information**, which offers guidance for each type of H1N1 vaccine available.

Please keep in mind that all significant adverse events that occur after the vaccination of adults and children, even if you are not sure whether the vaccine caused the adverse event, must be reported to the Vaccine Adverse Event Reporting System (VAERS). Information on submitting a VAERS report can be found at <http://vaers.hhs.gov/index>.

Share this information with your entire clinic staff involved in the H1N1 vaccination process, even if they do not personally administer vaccinations.

We appreciate the care you render to our members. Thank you for your attention to this notice. If you have any questions, please call Provider Services at **1-888-846-4262** (Medicaid) or **1-888-505-1201** (Medicare).

Thank you,

Ohana Health Plan

94-450 Mokuola Street, Suite  
106  
Waipahu, HI 96797  
Medicaid Toll-Free Telephone:  
(888) 846-4262  
Medicare Toll-Free Telephone:  
(888) 505-1201  
Web Address:  
[www.ohanahealthplan.com](http://www.ohanahealthplan.com)

## 2009 Influenza A (H1N1) Flu Vaccine Information

The CPT code for **MEDICAID** is **90470** and the CPT code for **MEDICARE** is **G9141**. The NDC Number is specific to each presentation and is located at the end of each package insert.

### H1N1 Vaccine Dosage Chart

Manufacturer	How Supplied	Age Group	Dosage & Route	Number of doses	Minimum Interval from dose 1 to 2
sanofi pasteur	0.25 mL prefilled syringe (PF); 0.5 mL prefilled syringe (PF); 5 mL multi-dose with preservative	6-35 months	0.25 mL IM	2 <sup>€</sup>	4 weeks**
		36 months through 9 yrs	0.5 mL IM	2 <sup>€</sup>	4 weeks**
		≥ 10 years of age & older	0.5 mL IM	1	
CSL	0.25 mL pre-filled syringe (PF); 0.5 mL prefilled syringe (PF); 5 mL multi-dose with preservative	6-35 months	0.25 mL IM	2 <sup>€</sup>	4 weeks**
		36 months through 9 yrs	0.5 mL IM	2 <sup>€</sup>	4 weeks**
		≥ 10 years of age & older	0.5 mL IM	1	
Novartis	0.5 mL prefilled syringe (PF); 5 mL multi-dose with preservative	4 through 9 years	0.5 mL IM	2 <sup>€</sup>	4 weeks**
		≥ 10 years of age & older	0.5 mL IM	1	
MedImmune	0.2 mL prefilled intranasal sprayer	2 through 9 years* <sup>§</sup> Children, adolescents & adults (10-49 years)	0.2 mL intranasal <sup>¶</sup>	2 <sup>€</sup> 1	4 weeks**

<sup>€</sup> FDA has approved two doses for children 6 months through 9 years of age.

\* Should not be administered to children under the age of 2 years, or to any person with asthma or child < 5 years of age with a history of asthma or wheezing.

<sup>§</sup> Intranasal vaccine is contraindicated in children and adolescents (2-17 years of age) receiving aspirin therapy or aspirin-containing therapy, because of the association of Reye's syndrome with aspirin and wild-type influenza infection.

<sup>¶</sup> Each 0.2 mL dose is administered as 0.1 mL per nostril.

\*\* CDC recommends that the two doses of 2009 H1N1 vaccine be separated by 4 weeks. However, based on previous studies of LAIV replication and immune response, as little as 14 days (2 weeks) might be sufficient to allow for an appropriate immune response to both vaccines. Therefore, an interval between the two types of LAIV of 2 weeks or more may be acceptable, although an interval of 28 is preferred.

### Contraindications:

- Hypersensitivity to egg proteins or any other vaccine components, or life-threatening reactions after previous administration of any influenza vaccine. Consult package insert @ <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm186102.htm>
- Moderate or severe illness with or without fever.

### Precautions:

- If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks.
- Immunocompromised persons may have a diminished immune response to Influenza A (H1N1) 2009 Monovalent Vaccine.

### Seasonal Flu Vaccine and H1N1 Vaccine Spacing:

Vaccine Types	Intervals
Inactivated + Inactivated	No interval
Inactivated + Live *	No interval
Live + Live <sup>€</sup>	4 week interval **

Persons who have received an injectable live virus vaccine (e.g., MMR, varicella) in past 4 weeks should wait 28 days before receiving LAIV.

\* Providers can administer seasonal and 2009 H1N1 inactivated vaccines, seasonal inactivated vaccine and 2009 H1N1 LAIV, or seasonal LAIV and inactivated 2009 H1N1 at the same visit, or at any time before or after each other but in different places on the body.

<sup>€</sup> Live attenuated seasonal and live 2009 H1N1 vaccines should NOT be administered at the same visit until further studies are done. If a person is eligible for the live vaccine, these vaccines should be separated by a minimum of four weeks.

\*\* CDC recommends that the two doses (for children 6 months through 9 years) of 2009 H1N1 vaccine be separated by 4 weeks.